Lucid Diagnostics (LUCD) Stock Statistics & Valuation Metrics

Lucid Diagnostics has a market cap or net worth of $201.72M. The enterprise value is -$34.56B.

Lucid Diagnostics has 176,945,970 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lucid Diagnostics’s return on equity (ROE) is -5.30 and return on invested capital (ROIC) is -5.49%.

The current PE Ratio of Lucid Diagnostics is ―. Lucid Diagnostics’s PEG ratio is 0.06.

In the last 12 months, Lucid Diagnostics had revenue of 4.71B and earned -58.01M in profits. Earnings per share was -0.69.

In the last 12 months, operating cash flow was -46.48M and capital expenditures -197.00K, giving a free cash flow of -46.68M billion.

Lucid Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Lucid Diagnostics upcoming earnings date is May 18, 2026, After Close (Confirmed).

Lucid Diagnostics as a current ratio of 1.31, with Debt / Equity ratio of 236.10%

In the past 12 months, Lucid Diagnostics has paid 0.00 in taxes.

Lucid Diagnostics EV to EBITDA ratio is 179.91, with an EV/FCF ratio of 0.19.

Lucid Diagnostics has $34.70B in cash and marketable securities with $25.82M in debt, giving a net cash position of $34.68B billion.

Gross margin is -0.06%, with operating margin of -1.05%, and net profit margin of -1.23%.

The average price target for Lucid Diagnostics is $2.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy